



Amniotic Fluid Embolism

Click the next button to continue...



Copyright © 2020 Shelly Betancourt and Michelle Becher

All rights reserved. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the publisher, except in the case of brief quotations embodied in critical reviews and certain other noncommercial uses permitted by copyright law. For permission requests, write to the publisher at the address below.

Maternal 911 Education Systems, LLC
475 West Center St.
Ithaca, MI 48847
www.maternal911.com

Maternal 911 and Maternal 911 in Action contains information designed as an educational resource to aid practitioners in providing obstetric care and the use of this information is voluntary. This information should not be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. It is not intended to substitute for the independent professional judgement. Maternal 911 reviews the publication regularly, but may not reflect the most recent evidence.

Maternal 911 makes every effort to present accurate and reliable information. The Maternal 911 and Maternal 911 in Action are publications provided 'as is' without any warranty of accuracy, reliability or otherwise, either express or implied. Maternal 911 does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither co-founder nor any officers, directors, members, employees, participants or agents will be liable for any loss, damage or claim with respect to liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.


Data from completing the modules may be used in research and publications with privacy maintained.



Course Description:

Amniotic Fluid Embolism (AFE) is a high acuity, low occurring process that when recognized may be life-saving. The course will help by giving understanding of the disease and its management. AFE is a detrimental disease process that is life threatening for the women it effects. The AFE module will provide knowledge for this low occurring process.

Approximate Time to Complete: 40 minutes



The purpose of this module is to improve participant's understanding of amniotic fluid embolism.

- Explain how amniotic fluid embolism can occur.
- Identify risks associated with amniotic fluid embolism syndrome.
- Recognize the signs and symptoms of amniotic fluid embolism so prompt health care delivery can be implemented.
- Initiate the initial steps of amniotic fluid embolism resuscitation with the application of equipment.
- Describe the medications used for resuscitation and how they may affect the mother and fetus.

-  Amniotic Fluid Embolism
 -  AFES
 -  Occurrence
 -  Risk Factors
 -  Etiology
-  Symptoms and Clinical Presentation
 -  Cardiogenic Shock
 -  Respiratory Failure
 -  Inflammation
 -  Clinical Presentation
-  Diagnosis and Management
 -  Diagnosis
 -  Management
 -  Catheters
 -  Oxygen
 -  Hemodynamics
 -  Vasoactive Agents
 -  IV Fluids
 -  Blood Products
 -  Delivery
 -  Prognosis and Complications
-  Summary
 -  Summary
 -  Course Completed Page



Amniotic fluid embolism syndrome (AFES)

- *Also called anaphylactoid syndrome of pregnancy.*
 - *A catastrophic condition that occurs during pregnancy or shortly after delivery [1-3].*
-
- First reported in 1926.
 - Not widely recognized until 1941.
 - In 1941, autopsies from a series of eight women who died from sudden shock during labor reported squamous cells and mucin of fetal origin in the maternal pulmonary vasculature [4,5].
 - These same fetal squamous cells have been described in the vascular beds of maternal renals, liver, spleen, pancreas and brain [6].





- AFES is different from venous thromboembolism and is reviewed in a separate module.
- The incidence rate is between 1-12 cases per 100,000 deliveries in most studies [7-12].

Several factors have been associated with AFES [7,12,13], including, but not limited to:

- Precipitous or tumultuous labor
- Advanced maternal age
- Cesarean and instrumental delivery
- Placenta previa, placental abruption, placenta accreta, percreta, or increta
- Grand multiparity (≥ 5 live births or stillbirths)
- Cervical lacerations
- Fetal distress
- Eclampsia
- Medical induction of labor
- Uterine rupture
- Polyhydramnios
- Miscarriage or abortion
- Amniocentesis

These factors are associated with the pathogenesis of AFES but not the direct cause.

AFES is best considered unpreventable and unpredictable.

Stage or duration of labor has not been associated with risk for AFES.




- The pathogenesis of AFES is thought to involve the amniotic fluid entering the maternal circulation through endocervical veins, the placental insertion site or a site of uterine trauma [14].
- Once the amniotic fluid reaches the maternal circulation, it can precipitate cardiogenic shock, respiratory failure and most likely, an inflammatory and anaphylactoid response.





- Amniotic fluid has been shown to cause occlusion and vasospasm of the maternal pulmonary vasculature with animal studies, resulting in rapid development of pulmonary hypertension, acute cor pulmonale and systemic hypotension [15-17].
 - In women with AFES, invasive hemodynamic studies seem to contradict these animal studies [18,19].
 - When elevated pulmonary arterial pressure, elevated pulmonary capillary wedge pressure, decreased cardiac output and decreased cardiac index are combined, it suggests the principal hemodynamic alteration in humans is left ventricular failure, rather than pulmonary hypertension and right ventricular failure.

- To reconcile the human and animal observations, a biphasic pattern of cardiogenic shock in AFES has been proposed [2,15,19].
- Initial acute pulmonary hypertension and right ventricular failure (usually lasting 15-30 minutes), according to the hypothesis, is followed by left ventricular dysfunction [20,21].
- Studies utilizing transesophageal echocardiography to non-invasively measure the hemodynamic parameters early during AFES, report vasospasm of the pulmonary vasculature, elevated pulmonary arterial pressure and right ventricular failure, thus supporting the bi-phasic hypothesis [20,21].
- The mechanism is unclear with the later phase left ventricular failure.



The mechanism may involve:

- Hypoxic injury to the left ventricle
- Release of maternal inflammatory mediators
- Direct depressant effect of amniotic fluid on the myocardium



Mouse over the heart to see what the mechanism may involve.



- Among patients with AFES, hypoxemia is the most common manifestation of the resultant respiratory failure.
- Hypoventilation can also occur.
- The primary cause of hypoxemia involves severe ventilation/perfusion (V/Q) mismatching.

**Factors contributing to
the V/Q mismatch [2] :**

- Acute pulmonary hypertension during the first phase of cardiogenic shock
- Cardiogenic pulmonary edema during the second phase

**Other contributors
may include [8, 22] :**

- Bronchospasm (about 15% of patients)
- Noncardiogenic pulmonary edema

- In 70% of patients who survive the first several hours, noncardiogenic pulmonary edema occurs [22].
- It generally develops as left ventricular dysfunction improves.
- Damage to the endothelial-alveolar membrane and capillary leak syndrome are evidence leading to high protein concentration in edematous fluid and the presence of amniotic debris in sputum and alveolar spaces.
- Widespread damage to the alveolar-capillary membrane causes non-cardiogenic edema to occur in AFES; it usually does not produce the clinical pattern typical of acute respiratory distress syndrome (ARDS).
- Women who survive the first few hours of AFES usually recover quite rapidly, whereas the course of ARDS tends to be protracted.



- Obstruction of the pulmonary vasculature seems unlikely to be the lone cause of AFES, since there is often a lag of many hours between the entry of amniotic fluid into the the maternal circulation and onset of symptoms and signs of AFES.
- Propositions have brought up how the lag may reflect evolution of AFES of an immunologic response or inflammatory reaction to the amniotic fluid.
- Support is evident by reports of decreased complement and increased inflammatory markers in some patients with AFES, including elevated serum tryptase levels and pulmonary mast cell activity [23-28].
- It is hypothesized that maternal circulation allows entry of fetal antigens via the amniotic fluid.
- The clinical manifestations and the severity may be related to the degree of immunologic stimulation or the balance of arachidonic acid metabolites such as leukotrienes in the amniotic fluid [29,30].



- The symptoms and signs associated with AFES have a typical onset during labor and delivery, or immediately postpartum [2].
- In rare instances, it has been reported following first or second trimester abortion, amniocentesis, or abdominal/uterine trauma, and as late as 48 hours after cesarean delivery or post partum, [8, 31-35].
- In a review of 272 cases, most women present with rapid cardiorespiratory collapse [10].
- Preceding the onset of dyspnea and hypotension may be nonspecific symptoms such as chills, nausea, vomiting and agitation [8,10].
- Tonic-clonic seizure activity may also occur.
- A less severe presentation of AFES, partial amniotic fluid embolism syndrome, may present with only some of the major symptoms and signs [15,36,37].
 - These patients with partial amniotic fluid embolism generally present with sudden onset of milder dyspnea and hypotension.
 - In this situation, the clinical course tends to be abbreviated and the prognosis much better compared to those who have the full syndrome.



The major clinical findings are the abrupt and fulminant onset of:



Click the terms in blue to learn more.

Hypotension due to cardiogenic shock

Disseminated intravascular coagulation (DIC)

Hypoxemia and respiratory failure

Coma or seizures

- A prominent feature of AFES is hypotension due to cardiogenic shock.
- When AFES occurs in women, approximately 85% die from cardiogenic shock or its complications [10].
- The management of cardiogenic shock may be complicated by cardiac dysrhythmias.
- The cardiac dysrhythmia could include pulseless electrical activity, bradycardia, ventricular fibrillation, and asystole [8].
- Management of the dysrhythmias is beyond the scope of this program.



The major clinical findings are the abrupt and fulminant onset of:



Click the terms in blue to learn more.

Hypotension due to cardiogenic shock

Disseminated intravascular coagulation (DIC)

Hypoxemia and respiratory failure

Coma or seizures

- A common early finding of AFES is profound hypoxemia.
- It is the most common manifestation of respiratory failure when AFES occurs.
- Hypoxemia is most commonly detected by pulse oximetry, but clinical findings include confusion, agitation, somnolence, dyspnea, tachycardia, tachypnea, cyanosis, and acidemia.
- Evidence may include crackles and radiographic air space disease when cardiogenic or noncardiogenic pulmonary edema is present.
- Wheezing is occasionally detected.
- Approximately 50% of the deaths are caused by profound hypoxemia and occur within the first hour of the AFE.
- Prolonged hypoxemia may lead to permanent, severe neurologic impairment or maternal brain death [8].



The major clinical findings are the abrupt and fulminant onset of:



Click the terms in blue to learn more.

Hypotension due to cardiogenic shock

Disseminated intravascular coagulation (DIC)

Hypoxemia and respiratory failure

Coma or seizures

- Nearly 80% of women with AFES develop disseminated intravascular coagulation (DIC) [1,2,8].
- DIC can begin 10-30 minutes after the onset of cardiopulmonary signs and symptoms. However, DIC may also be delayed by as many as four hours [2,38-41].
- The most common manifestations of DIC are prolonged bleeding from sites of invasive interventions, such as intravenous (IV) sites, and bruising.
- However, in some cases, major hemorrhage may be the clinical manifestation.
- When hemorrhage occurs, it can delay the diagnosis of AFES since an exhaustive search for structural causes of hemorrhage will likely occur [42].



The major clinical findings are the abrupt and fulminant onset of:



Click the terms in blue to learn more.

Hypotension due to cardiogenic shock

Disseminated intravascular coagulation (DIC)

Hypoxemia and respiratory failure


Coma or seizures

Encephalopathy (which may progress to a coma) associated with AFE is thought to be secondary to hypoxia and includes a spectrum of symptoms ranging from altered mental state to seizures. Tonic-clonic seizures are seen in 10-50% of patients [58].

AFES is diagnosed from clinical findings based on the constellation of clinical findings, rather than isolated signs and symptoms.

- AFES should be suspected whenever shock and/or respiratory compromise develops during labor or immediately postpartum.
- Other causes of sudden intrapartum or postpartum cardiorespiratory failure must be excluded.
- Sometimes the identification of amniotic fluid debris (squamous cells, trophoblastic cells, mucin, and lanugo) from blood samples drawn from the distal port of a pulmonary artery catheter.
- Such debris is common in maternal circulation without AFES, so finding the amniotic fluid debris alone should not be considered diagnostic [43] but should involve the constellation of signs and symptoms.

- There is no specific treatment for AFES.
- The therapeutic goal is to correct hypoxemia and hypotension so that ischemic consequences (i.e. hypoxic brain injury, acute kidney injury) are prevented in the mother and adequate oxygen delivery occurs to the fetus.



- Monitoring of maternal oxyhemoglobin saturation, heart rate and rhythm, and respiratory rate should be immediately initiated in all patients with suspected AFES.
- It is important to monitor the blood pressure non-invasively at frequent intervals until continuous blood pressure monitoring is established.
- Continuous monitoring of the fetal heart rate is desirable.

Catheters

- Following the initial assessment, plans should be made for both an arterial and a central venous catheter to be inserted.
- The initiation of therapies described below should not be delayed for catheter insertion as this procedure can be time consuming.
- The arterial catheter can be used to continuously monitor blood pressure.
- It also provides access to arterial blood for frequent measurement of arterial blood gases.

Slide 1 of 3



Catheters

The central venous catheter can be used to:

- Infuse IV fluids
- Infuse medications (i.e. vasopressors, inotropics, etc.)
- Infuse blood products
- Draw venous blood
- The central line can be used for limited hemodynamic monitoring by measuring the central venous pressure and the central venous oxyhemoglobin saturation.



Catheters

- Hemodynamic monitoring via a pulmonary arterial catheter should not be performed routinely.
- However, the central venous catheter may be helpful in selected patients [18,44,45] particularly those who have pulmonary edema, shock or uncertain intravascular volume.
- The central venous line allows invasive monitoring and helps to ensure the amount of IV fluid administered is enough to correct intravascular hypovolemia and optimize cardiac output, but not so much as to exacerbate pulmonary edema.
- In a study of a series of five patients with AFES who were managed with invasive hemodynamic monitoring, all five survived [18].

- Supplemental oxygen should be provided to all patients.
- Reaching a maternal oxygen tension (PaO₂) above 65 mmHg is a reasonable goal.
- To reach this goal, it often requires high flow rates of supplemental oxygen by facemask or invasive mechanical ventilation.
- When invasive mechanical ventilation can occur it provides additional options to improve oxygenation. The options include:
 - Increasing the fraction of inspired oxygen
 - Increasing the positive end-expiratory pressure
 - Prolonging or inverting the inspiratory to expiratory ratio.
 - Due to the associated high risk of aspiration, non-invasive positive pressure ventilation should be avoided during pregnancy.



- Factors impairing oxygen delivery to the fetus such as anemia or diminished cardiac output should be corrected.
- This may involve red blood cell transfusions and inotropic agents.
- If the woman has delivered, these factors (i.e. anemia, diminished cardiac output) should be corrected if there is evidence of persistent hypoperfusion despite optimization of the PaO₂.
- Common signs of hypoperfusion include:
 - Cool, vasoconstricted skin due to redirection of blood flow to core organs (however, warm flushed skin may be present early on in phases of sepsis)
 - Obtundation or restlessness
 - Oliguria or anuria
 - Lactic acidosis

- Maintaining a maternal PaO₂ greater than 65 mmHg has rationale by using women who have not delivered as an example.
- It is, however, similar for women who have delivered, but the primary concern shifts from end organ oxygen delivery to delivery of oxygen for the fetus.
- The delivery of fetal oxygen is directly related to umbilical vein oxygen tension, umbilical vein oxyhemoglobin saturation, fetal hemoglobin concentration, and maternal cardiac output.
- Healthy pregnant women have increased fetal hemoglobin concentration and maternal cardiac output. These compensate for low umbilical vein oxygen tension, so as to maintain sufficient fetal oxygen delivery.




- The compensatory increase of fetal hemoglobin and maternal cardiac output may not be adequate to maintain the fetal oxygenation in pregnant women who have an even lower umbilical vein oxygen tension due to systemic hypoxemia.
- The level has not been determined at which the compensatory mechanisms become inadequate for the degree of maternal hypoxemia.
 - This study exposed healthy pregnant women to low fractions of inspired oxygen, a maternal PaO₂ below 47 mmHg was associated with a decline in umbilical vein oxygen tension [46].
 - This PaO₂ is on the steep portion of the hemoglobin dissociation curve, where small changes in PaO₂ may cause large changes in oxyhemoglobin saturation and oxygen delivery.
 - It seems prudent, with this information, to maintain the maternal oxygen tension at a level that lies on the flat portion of the [hemoglobin dissociation curve](#) (i.e. > 65 mmHg). This is assuming there are no complicating abnormalities in maternal cardiac output, hemoglobin or pH.



Slide 4 of 4





Peter Southwood [CC0]: https://commons.wikimedia.org/wiki/File:Oxygen-Haemoglobin_dissociation_curves.svg

- Hypotensive patients are treated the same with AFES regardless if they have delivered or not.
- The intravascular volume status should be immediately assessed when the woman becomes hypotensive with evaluation by history and physical exam.
- For women who are intravascularly normovolemic or hypervolemic, a vasopressor is the preferred initial therapy.
- Two reasonable approaches exist for initial therapy for those women whose intravascular volume status is uncertain.
- First, empiric therapy can be initiated using a vasopressor.
 - This recommendation is based on the observations showing hypotension in AFES is almost always due to cardiogenic shock and coexisting intravascular hypovolemia is rare.
- Second, the pulmonary arterial catheter can help guide hemodynamic measurements to better adjust therapy.
 - Using this approach, the intravenous fluids are titrated to optimize cardiac output and cardiac filling pressures.
 - Vasopressors are then added to achieve the desired blood pressure once the volume status is optimized.
 - In the rare woman who has obvious intravascular hypovolemia, a trial of IV fluids is reasonable.

- When vasopressor therapy is warranted, norepinephrine and dopamine are the typical drugs of first choice.
- The inotrope, dobutamine, may be added and would likely be beneficial since it increases the low cardiac output and decreases the high afterload that is characteristic of cardiogenic shock.
- However, until the vasopressors have improved blood pressure, dobutamine should not be used.
- Dobutamine, when used alone, tends to reduce blood pressure by causing a drop in the systemic vascular resistance that is out of proportion to the increase in cardiac output.



Vasoactive Drugs

Vasopressors



Stimulates smooth muscle contraction of the capillaries & arteries

↓
Vasoconstriction

Inotropes



Increase the force of contraction of myocardial muscle

↓
Positive inotropism

↑
Rise in Mean Blood Pressure

↓
Improved tissue perfusion and oxygenation

- Vasopressors are used to treat hypotension in AFES even though they may diminish uteroplacental perfusion pressure.
- The rationale is found in the fact that untreated shock diminishes uteroplacental perfusion pressure and has numerous additional potential adverse consequences.

These include:

- Decreasing fetal oxygen delivery
- Increasing the mother's risk of ischemic complications
- Acute kidney injury
- Hypoxic brain injury
- Increasing mother's risk of death



- Pulmonary edema is common in AFES so a cautious approach is necessary whenever a trial of IV fluid is selected.
- When IV fluid is given, it is necessary to be administered in small boluses with recurrent assessment being required.
- The IV fluids should be discontinued when the intravascular volume has been replenished.
- The IV fluids should be promptly discontinued when new or worsening pulmonary edema occurs.
- When the pulmonary edema worsens with a trial of IV fluids, these women should be regarded as having uncertain intravascular volume and may be better managed with vasoactive agents.



- As discussed, AFES most commonly occurs during labor and delivery or postpartum.
- When AFES presents intrapartum, the need for immediate delivery must be determined.
- Delivery is determined mother-by-mother but factors favoring delivery include:
 - Non-reassuring fetal heart rate tracing
 - Rapid and progressive deterioration of the mother's condition
 - The opinion that delivery of the fetus may facilitate maternal resuscitative efforts
 - When the cervix is fully dilated and the fetal head has descended to a station of at least +2/5, operative vaginal delivery is reasonable with a capable clinician.
 - Otherwise, an emergency cesarean delivery is indicated.
 - Consideration for peri-mortem cesarean may be warranted when maternal status is compromised

- Consideration for the peri-mortem cesarean is warranted when shock and cardiopulmonary resuscitative efforts fail to restore maternal circulation.
- Because brain damage begins at 5 minutes of anoxia, the procedure should be initiated at 4 minutes (the 4-minute rule) to deliver the healthiest fetus.
- If a mother has a resuscitatable cause of death, then her life may be saved as well by a prompt and timely cesarean delivery during CPR.
- Sadly, the clinicians are too often paralyzed by the horror of the maternal cardiac arrest and instinctively CPR is performed too long before turning to the perimortem delivery.
- This quick procedure may actually improve the situation for the mother and certainly save the infant's life [48].



- However, there is significant risk of major maternal morbidity or death when a cesarean is performed in the presence of coagulopathy.
 - Some clinicians recommend that operative intervention not begin until the coagulopathy is corrected.
 - Unfortunately, this is not always possible because the delay could lead to fetal death, further blood loss, and worsening of the coagulopathy.
- When a cesarean is performed, blood, fresh frozen plasma, platelets, and cryoprecipitate should be available and administered if there is any evidence of impaired coagulation:
 - Persistent bleeding without clotting from the incision
 - Needle site bleeding

Case reports have described novel interventions that have been successfully used in patients with AFES:

- A right ventricular device and inhaled nitric oxide have been used in patients with right ventricular failure and pulmonary hypertension [49,50].
- In patients with severe left ventricular failure and hypoxemia, the following have been utilized: cardiopulmonary bypass, intraaortic balloon pump counterpulsation and extracorporeal membrane oxygenation (ECMO) [21,51].
- The use of recombinant human factor VIIa (rVIIa) may be utilized when severe coagulopathy and bleeding, especially in those undergoing surgery to control postpartum hemorrhage. [50,52].
- Unfortunately, rVIIa use in AFE may be associated with thrombotic morbidity and mortality (i.e. stroke and pulmonary embolism).

Maternal

Neonatal



Click the blue buttons to learn more.

- Much more unfortunate is the maternal mortality rate due to AFES has been reported between 10 to 90% [1,7,8,53-56], although more recent data suggest overall mortality rates may be closer to 20 percent [7,11,12].
- Even those surviving AFES generally have a poor outcome with as many as 85% suffering significant neurologic injury due to cerebral hypoxia [2,8].
- AFES is one of the leading causes of maternal mortality and is reported to cause ten percent of all maternal deaths in developed countries [56].



Case reports have described novel interventions that have been successfully used in patients with AFES:

- A right ventricular device and inhaled nitric oxide have been used in patients with right ventricular failure and pulmonary hypertension [49,50].
- In patients with severe left ventricular failure and hypoxemia, the following have been utilized: cardiopulmonary bypass, intraaortic balloon pump counterpulsation and extracorporeal membrane oxygenation (ECMO) [21,51].
- The use of recombinant human factor VIIa (rVIIa) may be utilized when severe coagulopathy and bleeding, especially in those undergoing surgery to control postpartum hemorrhage. [50,52].
- Unfortunately, rVIIa use in AFE may be associated with thrombotic morbidity and mortality (i.e. stroke and pulmonary embolism).

Maternal

Neonatal



Click the blue buttons to learn more.

- Neonatal outcomes are also poor.
 - The mortality rate is estimated to be between 20 and 60% [8,9].
 - Only 50% of survivors are neurologically intact.
- When the mother sustains an an AFE-induced cardiac arrest, overall neonatal outcomes have improved with prompt delivery of the fetus [57].





- AFES is a catastrophic condition that occurs during pregnancy or shortly after delivery.
- AFES is characterized by abrupt and fulminant onset of hypotension due to cardiogenic shock, hypoxemia, respiratory failure, and DIC.
- AFES is unpredictable, unpreventable, and rare (occurring once in every 8,000 to 80,000 deliveries).
- AFES is a clinical diagnosis that is based upon the constellation of clinical findings.
- Clinicians should suspect AFES whenever shock or respiratory compromise develops during labor and delivery, or immediately postpartum.
- Other causes of sudden intrapartum or postpartum cardiorespiratory failure must be excluded.




Click each box to review the course.





- There is no specific treatment for AFES.
- However, the goal is to expeditiously correct hypoxemia and hypotension so that ischemic consequences such as hypoxic brain injury, acute kidney disease, and myocardial injury are avoided in the mother and adequate oxygen is delivered to the fetus.
- This may require mechanical ventilation, vasopressors, inotropes, intravenous fluids, and blood products.
- Maternal mortality due to AFES remains high, although less than in previous years.
- This most likely reflects early recognition of the syndrome and appropriate aggressive therapy.
- Unfortunately, those who do survive generally have a poor outcome, most often caused by neurologic injury due to cerebral hypoxemia.
- Neonatal outcomes are also poor, although they improve with early delivery.



Congratulations!

You have successfully completed this module.

*Click on the above 'X' to take the post-test for this course.
If you do not attain a passing score after two attempts at the post-test the entire program must be repurchased.*

1. Practice Bulletin No. 183: Postpartum Hemorrhage. Committee on Practice Bulletins-Obstetrics Obstet Gynecol. 2017;130(4):e168.
2. <https://www.cmqcc.org/resource/ob-hem-emergency-management-plan-table-chart>
3. Sheldon WR, Blum J, Vogel JP, Souza JP, Gülmezoglu AM, Winikoff B. WHO Multicountry Survey on Maternal and Newborn Health Research Network. Postpartum haemorrhage management, risks, and maternal outcomes: findings from the World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG. 2014;121 Suppl 1:5
4. Callaghan WM, Kuklina EV, Berg CJ. Trends in postpartum hemorrhage: United States, 1994-2006. Am J Obstet Gynecol. 2010;202(4):353.e1.
5. Sheiner E, Sarid L, Levy A, Seidman DS, Hallak M. Obstetric risk factors and outcome of pregnancies complicated with early postpartum hemorrhage: a population-based study. J Matern Fetal Neonatal Med. 2005;18(3):149.
6. Mhyre JM, Shilkrot A, Kuklina EV, Callaghan WM, Creanga AA, Kaminsky S, Bateman BT. Massive blood transfusion during hospitalization for delivery in New York State, 1998-2007. Obstet Gynecol. 2013;122(6):1288.
7. Bateman BT, Berman MF, Riley LE, Leffert LR. The epidemiology of postpartum hemorrhage in a large, nationwide sample of deliveries. Anesth Analg 2010; 110:1368.
8. Rouse DJ, Leindecker S, Landon M, et al. The MFMU Cesarean Registry: uterine atony after primary cesarean delivery. Am J Obstet Gynecol 2005; 193:1056.
9. Cheng YW, Delaney SS, Hopkins LM, Caughey AB. The association between the length of first stage of labor, mode of delivery, and perinatal outcomes in women undergoing induction of labor. Am J Obstet Gynecol 2009; 201:477.e1.
10. Blomberg M. Maternal obesity and risk of postpartum hemorrhage. Obstet Gynecol 2011; 118:561.
11. Wetta LA, Szychowski JM, Seals S, et al. Risk factors for uterine atony/postpartum hemorrhage requiring treatment after vaginal delivery. Am J Obstet Gynecol 2013; 209:51.e1.
12. Kramer MS, Berg C, Abenhaim H, et al. Incidence, risk factors, and temporal trends in severe postpartum hemorrhage. Am J Obstet Gynecol 2013; 209:449.e1.
13. Sharp GC, Saunders PT, Greene SA, et al. Intergenerational transmission of postpartum hemorrhage risk: analysis of 2 Scottish birth cohorts. Am J Obstet Gynecol 2014; 211:51.e1.
14. Bruning AH, Heller HM, Kieviet N, et al. Antidepressants during pregnancy and postpartum hemorrhage: a systematic review. Eur J Obstet Gynecol Reprod Biol 2015; 189:38.
15. Oberg AS, Hernández-Díaz S, Frisell T, et al. Genetic contribution to postpartum haemorrhage in Swedish population: cohort study of 466,686 births. BMJ 2014; 349:g4984.
16. Giannella L, Mfuta K, Pedroni D, et al. Delays in the delivery room of a primary maternity unit: a retrospective analysis of obstetric outcomes. J Matern Fetal Neonatal Med 2013; 26:593.
17. Grzeskowiak LE, McBain R, Dekker GA, Clifton VL. Antidepressant use in late gestation and risk of postpartum haemorrhage: a retrospective cohort study. BJOG 2016; 123:1929.
18. Nyfløt LT, Sandven I, Oldereid NB, et al. Assisted reproductive technology and severe postpartum haemorrhage: a case-control study. BJOG 2017; 124:1198.

19. Lukes AS, Kadir RA, Peyvandi F, Kouides PA. Disorders of hemostasis and excessive menstrual bleeding: prevalence and clinical impact. *Fertil Steril*. 2005;84(5):1338.
20. Kadir RA, Lee CA, Sabin CA, Pollard D. Pregnancy in women with von Willebrand's disease or factor XI deficiency. *Economides DL Br J Obstet Gynaecol*. 1998;105(3):314.
21. Zehnder JL, Leung LL. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. *Blood*. 1990;76(10):2011.
22. Kadir RA, Kingman CE, Chi C, et al. Is primary postpartum haemorrhage a good predictor of inherited bleeding disorders? *Haemophilia* 2007; 13:178.
23. Kadir RA, Aledort LM. Obstetrical and gynaecological bleeding: a common presenting symptom. *Clin Lab Haematol* 2000; 22 Suppl 1:12.
24. Marshall AL, Durani U, Bartley A, Hagen CE, Ashrani A, Rose C, Go RS, Pruthi RK. The impact of postpartum hemorrhage on hospital length of stay and inpatient mortality: a National Inpatient Sample-based analysis. *Am J Obstet Gynecol*. 2017;217(3):344.e1.
25. Rizvi F, Mackey R, Barrett T, et al. Successful reduction of massive postpartum haemorrhage by use of guidelines and staff education. *BJOG* 2004; 111:495.
26. Shields LE, Wiesner S, Fulton J, Pelletreau B. Comprehensive maternal hemorrhage protocols reduce the use of blood products and improve patient safety. *Am J Obstet Gynecol* 2015; 212:272.
27. Skupski DW, Brady D, Lowenwirt IP, et al. Improvement in Outcomes of Major Obstetric emorrhage Through Systematic Change. *Obstet Gynecol* 2017; 130:770.
28. Shields LE, Smalarz K, Reffigee L, et al. Comprehensive maternal hemorrhage protocols improve patient safety and reduce utilization of blood products. *Am J Obstet Gynecol* 2011; 205:368.e1.
29. http://www.jointcommission.org/Sentinel_Event_Alert_Issue_30_Preventing_infant_death_and_injury_during_delivery_Additional_Resources/
30. Maslovitz S, Barkai G, Lessing JB, Ziv A, Many A. Recurrent obstetric management mistakes identified by simulation. *Obstet Gynecol*. 2007;109(6):1295
31. Deering SH, Chinn M, Hodor J, Benedetti T, Mandel LS, Goff B. Use of a postpartum hemorrhage simulator for instruction and evaluation of residents. *J Grad Med Educ*. 2009 Dec;1(2):260-3.
32. Joint Commission on Accreditation of Healthcare Organizations. JCAHO sentinel event alert #30. 2004.
33. Kohn, LT, Corrigan, JM, Donaldson, MS, Eds; Committee on Quality of Health Care in America, Institute of Medicine. *To Err Is Human: Building a Safer Health System*. Washington, DC: National Academy Press; 1999.
34. ACOG Committee Opinion No. 447: Patient safety in obstetrics and gynecology. American College of Obstetricians and Gynecologists Committee on Patient Safety and Quality Improvement. *Obstet Gynecol*. 2009;114(6):1424.
35. Dahlke JD, Mendoz-Figueroa H, Maggio L, et al. Prevention and management of postpartum hemorrhage: a comparison of 4 national guidelines. *Am J Obstet Gynecol* 2015; 213.e1

36. James, AH, McLintock, C., Lockhart, E. Postpartum hemorrhage: when uterotonics and sutures fail. *Am J Hematol* 2012; 87 Suppl 1:S16.
37. Munn, M.B., Owen, J., Vincent, R., et al. Comparison of two oxytocin regimens to prevent uterine atony at cesarean delivery: a randomized controlled trial. *Obstet Gynecol* 2001; 98:386.
38. Mousa, H. A., Blum, J., Abou, E., Senoun, G., et al. Treatment for primary postpartum haemorrhage. *Cochrane Database Syst Rev* 2014; :CD003249.
39. Hofmeyr, G. J., Gulmezoglu, A. M., Novikova, N., Lawrie, T. A. Postpartum misoprostol for preventing maternal mortality and morbidity. *Cochrane Database Syst Rev* 2013; :CD 008982.
40. Hofmeyr GJ, Walraven G, Gülmezoglu AM, et al. Misoprostol to treat postpartum haemorrhage: a systematic review. *BJOG* 2005; 112:547.
41. O'Brien P, El-Refaey H, Gordon A, et al. Rectally administered misoprostol for the treatment of postpartum hemorrhage unresponsive to oxytocin and ergometrine: a descriptive study. *Obstet Gynecol* 1998; 92:212.
42. Lokugamage AU, Sullivan KR, Niculescu I, et al. A randomized study comparing rectally administered misoprostol versus Syntometrine combined with an oxytocin infusion for the cessation of primary post partum hemorrhage. *Acta Obstet Gynecol Scand* 2001; 80:835.
43. Walraven G, Dampha Y, Bittaye B, et al. Misoprostol in the treatment of postpartum haemorrhage in addition to routine management: a placebo randomised controlled trial. *BJOG* 2004; 111:1014.
44. Hofmeyr GJ, Ferreira S, Nikodem VC, et al. Misoprostol for treating postpartum haemorrhage: a randomized controlled trial [ISRCTN72263357]. *BMC Pregnancy Childbirth* 2004; 4:16.
45. Blum J, Winikoff B, Raghavan S, et al. Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double-blind, randomised, non-inferiority trial. *Lancet* 2010; 375:217.
46. Winikoff B, Dabash R, Durocher J, et al. Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double-blind, randomised, non-inferiority trial. *Lancet* 2010; 375:210.
47. Hofmeyr GJ, Gülmezoglu AM, Novikova N, et al. Misoprostol to prevent and treat postpartum haemorrhage: a systematic review and meta-analysis of maternal deaths and dose-related effects. *Bull World Health Organ* 2009; 87:666.
48. Hofmeyr GJ, Walraven G, Gülmezoglu AM, et al. Misoprostol to treat postpartum haemorrhage: a systematic review. *BJOG* 2005; 112:547.
49. Tang OS, Schweer H, Seyberth HW, et al. Pharmacokinetics of different routes of administration of misoprostol. *Hum Reprod* 2002; 17:332.
50. Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. *Int J Gynaecol Obstet* 2007; 99 Suppl 2:S160.
51. Shojai R, Desbrière R, Dhifallah S, et al. [Rectal misoprostol for postpartum hemorrhage]. *Gynecol Obstet Fertil* 2004; 32:703.
52. Nasr A, Shahin AY, Elsamman AM, et al. Rectal misoprostol versus intravenous oxytocin for prevention of postpartum hemorrhage. *Int J Gynaecol Obstet* 2009; 105:244.

53. Anandakrishnan S, Balki M, Farine D, et al. Carbetocin at elective Cesarean delivery: a randomized controlled trial to determine the effective dose, part 2. *Can J Anaesth* 2013; 60:1054.
54. Chandler WL, Ferrell C, Trimble S, Moody S. Development of a rapid emergency hemorrhage panel. *Transfusion* 2010; 50:2547.
55. de Lloyd L, Bovington R, Kaye A, et al. Standard haemostatic tests following major obstetric haemorrhage. *Int J Obstet Anesth* 2011; 20:135.
56. Hiippala ST, Myllylä GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. *Anesth Analg* 1995; 81:360.
57. Su LL, Chong YS, Samuel M. Oxytocin agonists for preventing postpartum haemorrhage. *Cochrane Database Syst Rev* 2007; :CD005457.
58. Anandakrishnan S, Balki M, Farine D, et al. Carbetocin at elective Cesarean delivery: a randomized controlled trial to determine the effective dose, part 2. *Can J Anaesth* 2013; 60:1054.
59. Howard TF, Grobman WA. The relationship between timing of postpartum hemorrhage interventions and adverse outcomes. *Am J Obstet Gynecol* 2015; 213:239.e1.
60. Hsu S, Rodgers B, Lele A, Yeh J. Use of packing in obstetric hemorrhage of uterine origin. *J Reprod Med* 2003; 48:69.
61. Belfort MA, Dildy GA, Garrido J, White GL. Intraluminal pressure in a uterine tamponade balloon is curvilinearly related to the volume of fluid infused. *Am J Perinatol* 2011; 28:659.
62. Spahn DR, Rossaint R. Coagulopathy and blood component transfusion in trauma. *Br J Anaesth* 2005; 95:130.
63. Fuller AJ, Bucklin B. Blood component therapy in obstetrics. *Obstet Gynecol Clin North Am* 2007; 34:443.
64. Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. *J Thromb Haemost* 2007; 5:266.
65. Cortet M, Deneux-Tharaux C, Dupont C, et al. Association between fibrinogen level and severity of postpartum haemorrhage: secondary analysis of a prospective trial. *Br J Anaesth* 2012; 108:984.
66. Collins PW, Lilley G, Bruynseels D, et al. Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study. *Blood* 2014; 124:1727.
67. van der Bom JG. Viscoelastometric testing, fibrinogen and transfusion during post-partum haemorrhage. *Br J Anaesth* 2017; 119:352.
68. Gayat E, Resche-Rigon M, Morel O, et al. Predictive factors of advanced interventional procedures in a multicentre severe postpartum haemorrhage study. *Intensive Care Med* 2011; 37:1816.
69. Lousquy R, Morel O, Soyer P, et al. Routine use of abdominopelvic ultrasonography in severe postpartum hemorrhage: retrospective evaluation in 125 patients. *Am J Obstet Gynecol* 2011; 204:232.e1.
70. Elmer J, Wilcox SR, Raja AS. Massive transfusion in traumatic shock. *J Emerg Med* 2013; 44:829.
71. Ho KM, Leonard AD. Concentration-dependent effect of hypocalcaemia on mortality of patients with critical bleeding requiring massive transfusion: a cohort study. *Anaesth Intensive Care* 2011; 39:46.

72. Mount DB, Zandi-Nejad K. Disorders of potassium balance. In: Brenner and Rector's The Kidney, 8th ed, Brenner BM (Ed), WB Saunders Co, Philadelphia 2008. p.547.
73. Burtelow M, Riley E, Druzin M, et al. How we treat: management of life-threatening primary postpartum hemorrhage with a standardized massive transfusion protocol. *Transfusion* 2007; 47:1564.
74. Gonzalez EA, Moore FA, Holcomb JB, et al. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. *J Trauma* 2007; 62:112.
75. Roback JD, Caldwell S, Carson J, et al. Evidence-based practice guidelines for plasma transfusion. *Transfusion* 2010; 50:1227.
76. Spahn DR, Bouillon B, Cerny V, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. *Crit Care* 2013; 17:R76.
77. Allard S, Green L, Hunt BJ. How we manage the haematological aspects of major obstetric haemorrhage. *Br J Haematol* 2014; 164:177.
78. Holcomb JB, Jenkins D, Rhee P, et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. *J Trauma* 2007; 62:307.
79. Ketchum L, Hess JR, Hiippala S. Indications for early fresh frozen plasma, cryoprecipitate, and platelet transfusion in trauma. *J Trauma* 2006; 60:S51.
80. Davenport R, Curry N, Manson J, et al. Hemostatic effects of fresh frozen plasma may be maximal at red cell ratios of 1:2. *J Trauma* 2011; 70:90.
81. Pasquier P, Gayat E, Rackelboom T, et al. An observational study of the fresh frozen plasma: red blood cell ratio in postpartum hemorrhage. *Anesth Analg* 2013; 116:155.
82. Abdel-Razeq SS, Campbell K, Funai EF, et al. Normative postpartum intraabdominal pressure: potential implications in the diagnosis of abdominal compartment syndrome. *Am J Obstet Gynecol* 2010; 203:149.e1.
83. Geerts WH, Code KI, Jay RM, et al. A prospective study of venous thromboembolism after major trauma. *N Engl J Med* 1994; 331:1601.
84. Pacheco LD, Saade GR, Gei AF, Hankins GD. Cutting-edge advances in the medical management of obstetrical hemorrhage. *Am J Obstet Gynecol* 2011; 205:526.
85. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. *Lancet*. 2017.
86. WOMAN Trial Collaborators. 2017. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. *Lancet*. 389(10084):2105-2116. doi: 10.1016/S0140-6736(17)30638-4.